CommercialCoverageLow impact
08.02.14a, Casgevy™ (exagamglogene autotemcel)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has reissued the policy for Casgevy™ (exagamglogene autotemcel), a gene therapy treatment. This is a pharmacy policy update with a future effective date of April 29, 2026.
Action Required
By April 29, 2026: Review updated Casgevy™ gene therapy policy requirements at medpolicy.ibx.com. Monitor for specific billing codes, prior authorization requirements, and coverage criteria updates as the effective date approaches. This rare gene therapy primarily affects hematology practices treating sickle cell disease and beta-thalassemia.